Pisciotta, John M.Scholl, Peter F.Shuman, Joel L.Shualev, VladimirSullivan, David J.2020-01-222020-01-222017-04-012211-3207S2211-3207(16)30084-7 (PII)http://hdl.handle.net/10919/96532The incidence and global distribution of chloroquine resistant (CR) Plasmodium vivax infection has increased since emerging in 1989. The mechanism of resistance in CR P. vivax has not been defined. The resistance likely relates to the formation and disposition of hemozoin as chloroquine's primary mechanism of action involves disruption of hemozoin formation. CR P. berghei strains, like CR P. vivax strains, are confined to reticulocyte host cells and reportedly they do not accumulate appreciable intraerythrocytic hemozoin. Reports comparing hemozoin production between P. vivax strains and CR to chloroquine sensitive (CS) P. berghei are absent. Here we compare in vivo patterns of hemozoin formation and distribution in blood, spleen and liver tissue of male Swiss mice infected with CS or CR P. berghei not treated with chloroquine and CR P. berghei also treated with chloroquine. Light microscopy, laser desorption mass spectrometry and a colorimetric hemozoin assay detect trace hemozoin in the blood of CR P. berghei infected mice but significant hemozoin accumulation in liver and spleen tissue. Field emission in lens scanning electron microscopy reveals CR P. berghei hemozoin crystals are morphologically smaller but similar to those formed by CS parasites. CR P. berghei produces approximately five-fold less total hemozoin than CS strain. Lipid analysis of CS and CR P. berghei sucrose gradient purified bloodstage hemozoin indicates a similar lipid environment around the isolated hemozoin, predominately monopalmitic glycerol and monostearic glycerol. In contrast to CR and CS P. berghei, colorimetric hemozoin analysis of P. vivax strains indicates similar amounts of hemozoin are produced despite differing chloroquine sensitivities. These results suggest CR P. berghei forms significant hemozoin which accumulates in liver and spleen tissues and that the P. vivax chloroquine resistance mechanism differs from P. berghei.Pages 110-11910 page(s)application/pdfenCreative Commons Attribution-NonCommercial-NoDerivatives 4.0 InternationalParasitologyPharmacology & PharmacyHemozoinChloroquine resistancePlasmodium bergheiPlasmodium vivaxCHLOROQUINE RESISTANCEHEMOGLOBIN CATABOLISMINFECTED ERYTHROCYTESMALARIA PARASITEFALCIPARUMHEMEPROTEINPFCRTQUANTIFICATIONDEGRADATION1108 Medical MicrobiologyLiverSpleenAnimalsMicePlasmodium bergheiPlasmodium falciparumPlasmodium vivaxParasitemiaMalariaMalaria, VivaxChloroquineHemeproteinsAntimalarialsDrug ResistanceArticle - Refereed2020-01-22https://doi.org/10.1016/j.ijpddr.2017.02.00171282799452211-3207